Vivos Therapeutics more than doubles as FDA clears sleep apnea device

Vivos Therapeutics

29/11/2023 13:15

** Shares of Vivos Therapeutics  VVOS.O  more than double to
$9.12 in premarket trading
    ** Co says its oral medical device to treat severe
obstructive sleep apnea has been granted clearance by the U.S.
FDA
    ** VVOS says the device is an alternative to machines made
by Philips  PHG.AS  and ResMed  RMD.N  that send pressurized air
into one's nose and mouth during sleep
     ** Study data, submitted to the FDA for clearance, shows at
least 50% of patients saw an improvement in the index that
measures the number of apneas that occur per hour of sleep  
    ** Up to Tuesday's close, stock down 56.3% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))